Substance Structure, production process and indented use Is there adequate published safety data and exposure data for this substance to meet current GRAS.

Slides:



Advertisements
Similar presentations
Inadequacies in the Federal Regulation of Agricultural Biotechnology Gregory Jaffe Director, Biotechnology Project Center for Science in the Public Interest.
Advertisements

Product Documentation Chapter 5. Title 21 of the Code of Federal Regulations  Volume 1: Parts 1-99 (FDA, General)  Volume 2: Parts (FDA, Food.
CODE OF PRACTICE AND COMMODITIES STANDARDS, PRESENTED AT NIGERIA AFLATOXIN WORKSHOP BY STANDARDS ORGANISATION OF NIGERIA.
CONFERENCE ON “ FOOD ADDITIVES : SAFETY IN USE AND CONSUMER CONCERNS“ JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY NAIROBI, 24 JUNE 2014.
Determine impurity level in relevant batches1
Regulation and Safety Assessment of Novel Foods in Canada William Yan, Ph.D. Office of Food Biotechnology Health Canada.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Regulatory and Industry Requirements for Botanical Drug Products Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University.
What Do Toxicologists Do?
Special Topics in IND Regulation
Stefan Franzén Introduction to clinical trials.
Food Safety Assessment Kevin Greenlees, PhD, DABT Kathleen Jones, PhD.
Cellular Therapies for Cardiac Diseases – FDA Preclinical Perspective Richard D. McFarland Ph.D., M.D. CBER/OCTGT/DCEPT BRMAC # 37 March 18-19, 2004.
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
1 REACh Registration, Evaluation and Authorization of Chemicals and Restriction! Ohio Valley SOT Wednesday, August 26, 2009 REACh: The New Toxicology Frontier.
COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
FDA’s Policy for Evaluating Bioengineered Foods Jeanette Glover Glew Food and Drug Administration Center For Food Safety and Applied Nutrition September,
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
DSHEA and Bioavailability Elizabeth A. Yetley, Ph.D. Ctr. Food Safety & Applied Nutrition Food and Drug Administration.
Animal Feed GRAS Notifications Geoffrey K. Wong, M.S. Division of Animal Feeds Center for Veterinary Medicine Pet Food Institute Pet Food Institute October.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
Sources of Uncertainty and Current Practices for Addressing Them: Exposure Perspective Clarence W. Murray, III, Ph.D. Center for Food Safety and Applied.
Codex Guidelines for the Application of HACCP
Probiotics: Safety Issues Francis B Palumbo, PhD, Esq. University of Maryland School of Pharmacy Center on Drugs & Public Policy.
SAFETY OF GENETICALLY MODIFIED FOODS E Jane Morris.
The Research Proposal. Purpose Guidelines for preparing and evaluating a research brief and proposal Understand the purpose of a research proposal in.
Preclinical Safety Assessment of Cosmetics & Toiletries Raman Govindarajan, MD, PhD. Regional Director Medical and Scientific Affairs Johnson and Johnson.
CVM’s Procedure for Setting Tolerances
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
Regulatory Procedure for the Assessment of GM Foods.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Training Session Product File Notes and Registration Reports, 23 October Product File Note Part Residues Frédéric Joris and Bruno Dujardin Federal.
Stefan Franzén Introduction to clinical trials.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
Dr. Manfred Wentz Director, Hohenstein Institutes (USA) Head, Oeko-Tex Certification Body (USA) AAFA – Environmental Committee Meeting November 10, 2008.
International Initiatives and the U.S. HPV Challenge Program Ken Geiser, PhD Lowell Center for Sustainable Production University of Massachusetts Lowell.
Food: What Statistics Say and Don’t Say Food Consumption Tends Food Additives and How They Are Regulated.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Exploratory IND Studies
Dietary Supplements. Definition by DSHEA Product that is to supplement a healthy diet. Includes ingredients such as vitamins, minerals, herbs, botanicals,
Product Documentation Chapter 5. Required Medical Device Documentation  Business proposal  Product specification  Design specification  Software.
Furan in Food Summary and Charge to the FAC and SCNT Terry C. Troxell, Ph.D. Director Office of Plant and Dairy Foods FDA Center for Food Safety and Applied.
Topics discussed in the presentation
Module 3 Risk Analysis and its Components. Risk Analysis ● WTO SPS agreement puts emphasis on sound science ● Risk analysis = integrated mechanism to.
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.
FAO/WHO Codex Training Package Module 4.3 FAO/WHO CODEX TRAINING PACKAGE SECTION FOUR – SCIENTIFIC BASIS FOR CODEX WORK 4.3 What is JECFA?
Nutraceuticals & New Dietary Ingredients The Swiss Perspective Willi Hunziker, DVM, MBA
Background on Furan in Foods Nega Beru, Ph.D. Director, Division of Plant Product Safety Office of Plant and Dairy Foods Center for Food and Applied Nutrition.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.
Genetically Modified Foods Beth Roberson November 19, 2004 FST 490.
© 2009 Hogan & Hartson LLP. All rights reserved. Toward Closer Cooperation in the New Decade? FDA Issues Martin J. Hahn Hogan & Hartson, L.L.P. NABCA 17.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
1. Consumers, Health, Agriculture and Food Executive Agency Risk assessment with regard to food and feed safety Risk analysis Why risk assessment in the.
1 IND Applications for Academic Clinical Investigations John Marler, MD US Food and Drug Administration New Hampshire Avenue White Oak, MD
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
In the name of God. Common Technical Document On Biotech.
for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.
Choosing Foods Wisely Chapter 02.
Safety of food additives: The regulatory Roadmap
Guidance for review of studies involving HCT/Ps and IND Basics
Safety of food additives: The regulatory Roadmap
Regulatory Sciences and Government Affairs
International Initiatives and the U.S. HPV Challenge Program
Quality guidelines on impurities
Quality guidelines on impurities
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

Substance Structure, production process and indented use Is there adequate published safety data and exposure data for this substance to meet current GRAS standards? Insufficient Data to Proceed NO YES Food Substance Decision Tree for Independent GRAS Determinations Assumptions Animal & Human Studies Conducted and Published Identify deficiencies Conduct Studies & Evaluate Data Make data publically available New to U.S. Food Market History of dietary exposure in other countries Assumptions: Substance has existing safety data in public literature Dietary exposure without previous FDA review/approval Approach: May require additional safety testing and publication of study results in support of GRAS status of proposed use (see FDA Redbook for testing guidelines) Must account for cumulative exposure of intended uses in safety assessment due to increase in dietary exposure Clinical studies may be required Safety concerns to consider are dependant on category of independent GRAS determination I Forgot what wording to put here…… Modified Production Manufacturing modification for currently FDA-approved or GRAS substances Assumptions: Substance has current FDA approval or GRAS status for use in food Substance has existing and adequate safety data in the public literature Approach: May require additional safety testing and publication of study results in support of GRAS status of proposed use (see FDA Redbook for testing guidelines) Extension of Food Use Extension of food uses for currently FDA-approved or GRAS substances Assumptions: Substance has current FDA approval or GRAS status for use in food Substance has existing and adequate safety data in the public literature Intended food uses may change with no increase in dietary exposure Approach: Perform/revise exposure estimates

ProteinsEnzyme Preparations Has the source of the enzyme or other proteins been well characterized and described? Potential for allergic response? Identities and levels of diluents, stabilizers, preservatives, and any other substances used in the enzyme/protein formulation Information on secondary enzymes/proteins derived from the production organism(s) that may be present in the enzyme/protein preparation. The content of total organic solids (TOS) for both the commercial enzyme/protein preparation and the enzyme/protein batch used in toxicology studies Does the enzyme/protein preparation conform to specifications for purity provided in the most recent relevant edition of the Food Chemicals Codex? ChemicalsLipids Extracts In the case that additional testing is required in order to achieve GRAS status the following considerations may be addressed General Testing Considerations ●Single Dose-animals & human ●Comparative biodisposition ● Repeated doses ● Subchronic dosing ● Genetic Toxicity ●Reproductive /developmental toxicity studies● Adequate for ADI * May refer to FDA Redbook for testing guidelines Carbohydrates Determine Natural Occurrence and Presence in the Human Diet Define Any History of Use and Consumption in U.S. Population Determine Current Regulatory Status of the Purified Carbohydrate in the USA and Identify Any Prior GRAS determinations for Its Use in Food in the Publicly Available Literature Develop Detailed Specifications/Description of the Purified Carbohydrate Prepare Full Chemical Characterization of the Purified Carbohydrate Provide Complete Manufacturing Process Description (Demonstration of Consistency/Reproducibility in Manufacturing Process)